Holen Sie sich die Stockscreener-App
42.16
7.03%
2.77
Handel nachbörslich:
41.32
-0.84
-1.99%
Schlusskurs vom Vortag:
$39.39
Offen:
$39.41
24-Stunden-Volumen:
1.85M
Relative Volume:
1.22
Marktkapitalisierung:
$2.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-15.44
EPS:
-2.73
Netto-Cashflow:
$-97.30M
1W Leistung:
+10.77%
1M Leistung:
+9.34%
6M Leistung:
+245.86%
1J Leistung:
+214.16%
1-Tages-Spanne:
$39.28
$42.71
1-Wochen-Bereich:
$35.31
$42.71
52-Wochen-Spanne:
$8.241
$42.71
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Vergleichen Sie MLYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
42.16 | 3.06B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics stock hits all-time high at 41.11 USD - Investing.com
Mineralys Therapeutics (NASDAQ:MLYS) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
What MACD signals say about Mineralys Therapeutics Inc.2025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Has Mineralys Therapeutics Inc. formed a bullish divergence2025 Sector Review & Safe Entry Zone Tips - newser.com
Published on: 2025-10-10 04:36:23 - newser.com
Is Mineralys Therapeutics Inc. stock reversal real or fakeJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Forecasting Mineralys Therapeutics Inc. price range with options dataTrade Signal Summary & Consistent Profit Trade Alerts - newser.com
Real time breakdown of Mineralys Therapeutics Inc. stock performanceJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Can Mineralys Therapeutics Inc. recover in the next quarterEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Mineralys Therapeutics Inc. stock chart pattern explainedJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Published on: 2025-10-09 03:22:25 - newser.com
Tick level data insight on Mineralys Therapeutics Inc. volatility2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Will Mineralys Therapeutics Inc. see short term momentumJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN
What drives Mineralys Therapeutics Inc stock priceEarnings Season Recap & Low Risk Trading Ideas - earlytimes.in
Can swing trading help recover from Mineralys Therapeutics Inc. lossesJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Applying Wyckoff theory to Mineralys Therapeutics Inc. stockWeekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
What’s next for Mineralys Therapeutics Inc. stock priceJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Mineralys Therapeutics Inc.’s volatility index tracking explained2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial - MyChesCo
Is Mineralys Therapeutics Inc. stock poised for growthTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Tools to assess Mineralys Therapeutics Inc.’s risk profileJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
Statistical indicators supporting Mineralys Therapeutics Inc.’s strengthJuly 2025 Action & Community Consensus Stock Picks - newser.com
Understanding Mineralys Therapeutics Inc.’s price movementTrade Signal Summary & Free Accurate Trade Setup Notifications - newser.com
What does recent volatility data suggest for Mineralys Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Top chart patterns to watch in Mineralys Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.2%Here's Why - MarketBeat
Could Mineralys Therapeutics (MLYS) Trial Progress Hint at a Broader Hypertension Strategy? - simplywall.st
Mineralys Therapeutics Announces Public Offering of Shares - MSN
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics Lead September 2025 Biotech Funding Rounds - geneonline.com
The biggest biotech funding rounds in September 2025 - Labiotech.eu
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance
A Fresh Look at Mineralys Therapeutics (MLYS) Valuation Following New Clinical Milestones for Lorundrostat - simplywall.st
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - MSN
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS) - Seeking Alpha
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - Sahm
Mineralys completes enrollment in phase 2 sleep apnea drug trial By Investing.com - Investing.com Nigeria
Mineralys at Stifel Forum: Lorundrostat’s Strategic Path - Investing.com India
Mineralys at Stifel Forum: Lorundrostat’s Strategic Path By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups - Insider Monkey
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):